🔥🐔 BizChicken 🐔🔥

Companies Similar to Eton Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Aytu BioPharma, Inc.

Aytu BioPharma, Inc. logo
Market Cap: Lowest
Employees: Low

Adzenys XR-ODT

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics and consumer healthcare products in the United States and internationally. They offer products for the treatment of ADHD, allergies, fluoride deficiency, cough, and insomnia.

Tags: ADHD, Allergies, Fluoride Deficiency, Healthcare, Insomnia, Pharmaceuticals, Therapeutics

Symbol: AYTU

Recent Price: $1.61

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Joshua R. Disbrow

Sector: Healthcare

Employees: 102

Address: 373 Inverness Parkway, Englewood, CO 80112

Phone: 720 437 6580

Last updated: 2024-12-31

DURECT Corporation

DURECT Corporation logo
Market Cap: Lowest
Employees: Lowest

ALZET

DURECT Corporation is a biopharmaceutical company that develops medicines based on its epigenetic regulator and pharmaceutical programs. It offers products like ALZET osmotic pumps for laboratory animal research, larsucosterol for treating liver diseases, and POSIMIR for post-surgical pain relief.

Tags: ALZET, POSIMIR, biopharmaceutical, epigenetic, larsucosterol, research

Symbol: DRRX

Recent Price: $0.85

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. James E. Brown D.V.M.

Sector: Healthcare

Employees: 48

Address: 10260 Bubb Road, Cupertino, CA 95014-4166

Phone: 408 777 1417

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bönnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

rezafungin acetate

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology. Their lead product candidate is rezafungin acetate, a novel echinocandin antifungal for treating invasive fungal infections.

Tags: Cloudbreak platform, anti-infectives, antifungal, biotechnology, infectious diseases, oncology, rezafungin acetate

Symbol: CDTX

Recent Price: $25.25

Industry: Biotechnology

CEO: Dr. Jeffrey L. Stein Ph.D.

Sector: Healthcare

Employees: 69

Address: 6310 Nancy Ridge Drive, San Diego, CA 92121

Phone: 858 752 6170

Last updated: 2024-12-31

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, Redi Trex

Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, offering various medications including injections and oral solutions.

Tags: gastroenterology, hospital care, oncology, pharmaceutical, prescription products, rheumatology

Symbol: CPIX

Recent Price: $2.42

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. A. J. Kazimi MBA

Sector: Healthcare

Employees: 91

Address: 2525 West End Avenue, Nashville, TN 37203

Phone: 615 255 0068

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

EGP-437

Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.

Tags: EGP-437, clinical stage, drug delivery, eye diseases, pharmaceutical, uveitis

Symbol: EYEG

Recent Price: $35.04

Industry: Biotechnology

CEO: Mr. Stephen From

Sector: Healthcare

Employees: 14

Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452

Phone: 17817889043

Leadership

  • Paul Chaney, Chairman of the Board
  • Morton F. Goldberg, MD, Director
  • Praveen Tyle, PhD, Director
  • Thomas Balland, Director
  • Thomas E. Hancock, Director
  • Bernard Malfroy-Camine, PhD, Director
  • Mounia Chaoui, PhD, Director

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. logo
Market Cap: Lowest
Employees: Lowest

QRX003

Quoin Pharmaceuticals, Ltd. is a specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases, including QRX003 for Netherton Syndrome.

Tags: Netherton Syndrome, QRX003, QRX004, QRX006, orphan diseases, pharmaceuticals, rare diseases, therapeutics

Symbol: QNRX

Recent Price: $0.70

Industry: Biotechnology

CEO: Dr. Michael Myers Ph.D.

Sector: Healthcare

Employees: 4

Address: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349

Phone: 703 980 4182

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

Spruce Biosciences, Inc.

Spruce Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tildacerfont

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders, with tildacerfont as a principal product targeting congenital adrenal hyperplasia.

Tags: biopharmaceutical, clinical trials, congenital adrenal hyperplasia, endocrine disorders, tildacerfont

Symbol: SPRB

Recent Price: $0.43

Industry: Biotechnology

CEO: Dr. Javier Szwarcberg M.D., M.P.H.

Sector: Healthcare

Employees: 22

Address: 2001 Junipero Serra Boulevard, Daly City, CA 94014

Phone: 415 655 4168

Leadership

  • Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer
  • Samir Gharib, M.B.A., President and Chief Financial Officer
  • Will Charlton, M.D., M.A.S., Chief Medical Officer
  • Heidi Petersen, M.P.H., Senior Vice President, Regulatory and Quality
  • P.J. Ramtin, Senior Vice President of Business Operations
  • Dasharatha Reddy, Ph.D., Vice President, Pharmaceutical Development and Manufacturing
  • Saba Sile, MD, Vice President, Clinical Development
  • Michael Grey, Executive Chairman
  • Tiba Aynechi, Ph.D., Independent
  • Percival Barretto-Ko, Independent
  • Bali Muralidhar, Ph.D., Partner, Abingworth LLP
  • Camilla V. Simpson, M.Sc., Independent
  • Dan Spiegelman, M.B.A., Independent
  • Kirk Ways, M.D., Ph.D., Independent

Last updated: 2024-12-31

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd. logo
Market Cap: High
Employees: Low

NURTEC ODT (rimegepant)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops product candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States.

Tags: biopharmaceutical, migraine treatment, neurological diseases, neuropsychiatric disorders, rare disorders

Symbol: BHVN

Recent Price: $35.78

Industry: Biotechnology

CEO: Dr. Vladimir Coric M.D.

Sector: Healthcare

Employees: 239

Address: 215 Church Street, New Haven, CT 06510

Phone: 203 404 0410

Last updated: 2024-12-31

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Ryanodex, Belrapzo, Bendeka, EP-4104, PEMFEXY, EA-114, Vasopressin

Eagle Pharmaceuticals, Inc. specializes in the development and commercialization of pharmaceutical products targeting diseases of the central nervous system, metabolic critical care, and oncology in the U.S. Notable products include Ryanodex for malignant hyperthermia, and oncology treatments Belrapzo and Bendeka.

Tags: antitoxin, central nervous system, collaboration agreements, critical care, disease treatment, oncology, pharmaceutical

Symbol: EGRX

Recent Price: $0.50

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Michael Graves

Sector: Healthcare

Employees: 134

Address: 50 Tice Boulevard, Woodcliff Lake, NJ 07677

Phone: 201 326 5300

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08